Alaunos Therapeutics, Inc. — Form 8-K
Filed October 21, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
Alaunos Therapeutics received notice of failure to satisfy continued listing rules or standards on October 21, 2026. The filing indicates a delisting or transfer of listing situation but does not specify the exact listing standard violated, remediation timeline, or specific financial metrics that triggered the notice.
Why this rating
Delisting is existential threat to $9.6M-cap company; loss of exchange access severely impairs capital raising, trading liquidity, and investor access. Business-altering event regardless of remedy outcome.
Extracted items
- 3.01 delisting notice
- 9.01 exhibits
Price action (we called it negative)
before filing · preread $3.15 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.